Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10a inhibitor mp-10 in its native environment

ACS Chemical Biology

Volumn 9, Issue 12, 2014, Pages 2823-2832

  Schülke, Jan Philip ^a   McAllister, Laura A ^a   Geoghegan, Kieran F ^a   Parikh, Vinod ^a   Chappie, Thomas A ^a   Verhoest, Patrick R ^a   Schmidt, Christopher J ^a   Johnson, Douglas S ^a   Brandon, Nicholas J ^a,b  

^a PFIZER INC   (United States)

^b Neuroscience Medicinal Chemistry and Chemical Biology Pfizer Worldwide Research and Development ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; UNCLASSIFIED DRUG; 2-((4-(1-METHYL-4-PYRIDIN-4-YL-1H-PYRAZOL-3-YL)PHENOXY)METHYL)QUINOLINE; MOLECULAR PROBE; PDE10A PROTEIN, HUMAN; PHOSPHODIESTERASE INHIBITOR; PROTEIN BINDING; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHEMOPROTEOMICS; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MEMBRANE; NONHUMAN; PHOTOAFFINITY LABELING; PROTEOMICS; RAT; WHOLE CELL; AFFINITY CHROMATOGRAPHY; ANIMAL; BINDING SITE; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; CORPUS STRIATUM; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; LIGHT; METABOLISM; MOLECULAR PROBE; NERVE CELL; PHOTOCHEMISTRY; PRIMARY CELL CULTURE; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

RODENTIA;

ANIMALS; BINDING SITES; CELL MEMBRANE; CHROMATOGRAPHY, AFFINITY; CORPUS STRIATUM; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGHT; MODELS, MOLECULAR; MOLECULAR PROBES; NEURONS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PHOTOCHEMICAL PROCESSES; PRIMARY CELL CULTURE; PROTEIN BINDING; PYRAZOLES; QUINOLINES; RATS;

EID: 84919598815     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb500671j     Document Type: Article

References (38)

1. Francis, S. H., Houslay, M. D., and Conti, M. (2011) Phosphodiesterase Inhibitors: Factors That Influence Potency, Selectivity, and Action, in Phosphodiesterases as Drug Targets (Francis, S. H., Conti, M., and Houslay, M. D., Eds.), pp 47-84. Springer: Berlin, Heidelberg.
2. Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., and Manganiello, V. C. (2014) Advances in targeting cyclic nucleotide phosphodiesterases Nat. Rev. Drug Discovery 13, 290-314
3. Menniti, F. S., Plath, N., Svenstrup, N., and Schmidt, C. J. (2014) Pharmacological Manipulation of Cyclic Nucleotide Phosphodiesterase Signaling for The Treatment of Neurological and Psychiatric Disorders In The Brain, in Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System (Brandon, N. J. and West, A. R., Eds.), pp 77-114, John Wiley & Sons, Inc., Hoboken, NJ.
4. Bender, A. T. and Beavo, J. A. (2006) Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use Pharmacol. Rev. 58, 488-520
5. Charych, E. I. and Brandon, N. J. (2014) Molecular and Cellular Understanding of PDE10A: A Dual-Substrate Phosphodiesterase with Therapeutic Potential to Modulate Basal Ganglia Function, in Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System (Brandon, N. J. and West, A. R., Eds.), pp 247-268. John Wiley & Sons, Inc., Hoboken, NJ.
6. Coskran, T. M., Morton, D., Menniti, F. S., Adamowicz, W. O., Kleiman, R. J., Ryan, A. M., Strick, C. A., Schmidt, C. J., and Stephenson, D. T. (2006) Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species J. Histochem. Cytochem. 54, 1205-1213
7. DeLong, M. R. and Wichmann, T. (2007) Circuits and Circuit Disorders of the Basal Ganglia Arch. Neurol. 64, 20-24
8. Giampa, C., Laurenti, D., Anzilotti, S., Bernardi, G., Menniti, F. S., and Fusco, F. R. (2010) Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntingtons Disease PLoS One 5 e13417
9. Grauer, S. M., Pulito, V. L., Navarra, R. L., Kelly, M. P., Kelley, C., Graf, R., Langen, B., Logue, S., Brennan, J., Jiang, L., Charych, E., Egerland, U., Liu, F., Marquis, K. L., Malamas, M., Hage, T., Comery, T. A., and Brandon, N. J. (2009) Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia J. Pharmacol. Exp. Ther. 331, 574-590
10. Schmidt, C. J., Chapin, D. S., Cianfrogna, J., Corman, M. L., Hajos, M., Harms, J. F., Hoffman, W. E., Lebel, L. A., McCarthy, S. A., Nelson, F. R., Proulx-LaFrance, C., Majchrzak, M. J., Ramirez, A. D., Schmidt, K., Seymour, P. A., Siuciak, J. A., Tingley, F. D., Williams, R. D., Verhoest, P. R., and Menniti, F. S. (2008) Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia J. Pharmacol. Exp. Ther. 325, 681-690
11. Li, N., Lee, K., Xi, Y., Zhu, B., Gary, B. D., Ramirez-Alcántara, V., Gurpinar, E., Canzoneri, J. C., Fajardo, A., Sigler, S., Piazza, J. T., Chen, X., Andrews, J., Thomas, M., Lu, W., Li, Y., Laan, D. J., Moyer, M. P., Russo, S., Eberhardt, B. T., Yet, L., Keeton, A. B., Grizzle, W. E., and Piazza, G. A. (2014) Phosphodiesterase 10A: A novel target for selective inhibition of colon tumor cell growth and catenin-dependent TCF transcriptional activity Oncogene 10.1038/onc.2014.94
12. Tian, X., Vroom, C., Ghofrani, H. A., Weissmann, N., Bieniek, E., Grimminger, F., Seeger, W., Schermuly, R. T., and Pullamsetti, S. S. (2011) Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling PLoS One 6 e18136
13. DeMartinis, N., Banerjee, A., Kumar, V., Boyer, S., Schmidt, C. J., and Arrojo, S. (2012) Results of a Phase 2A Proof-of-Concept Trial with a PDE10A Inhibitor in the Treatment of Acute Exacerbation of Schizophrenia. Poster 212, Presented at the Society for Biological Psychiatry 2012 Annual Meeting Philadelphia, PA.
14. Bunnage, M. E., Chekler, E. L. P., and Jones, L. H. (2013) Target validation using chemical probes Nat. Chem. Biol. 9, 195-199
15. Simon, G. M., Niphakis, M. J., and Cravatt, B. F. (2013) Determining target engagement in living systems Nat. Chem. Biol. 9, 200-205
16. Geoghegan, K. F. and Johnson, D. S. (2010) Chemical Proteomic Technologies for Drug Target Identification, in Annual Reports in Medicinal Chemistry, Chapter 21, pp 345-360. Academic Press, San Diego, CA.
17. Ziegler, S., Pries, V., Hedberg, C., and Waldmann, H. (2013) Target identification for small bioactive molecules: finding the needle in the haystack Angew. Chem., Int. Ed. 52, 2744-2792
18. Niphakis, M. J. and Cravatt, B. F. (2014) Enzyme inhibitor discovery by activity-based protein profiling Annu. Rev. Biochem. 83, 341-377
19. Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E., Herring, C., Nordin, B., Weissig, H., Yang, Q., Lee, J.-D., Gray, N. S., and Kozarich, J. W. (2011) In situ kinase profiling reveals functionally relevant properties of native kinases Chem. Biol. 18, 699-710
20. Salisbury, C. M. and Cravatt, B. F. (2008) Optimization of Activity-Based Probes for Proteomic Profiling of Histone Deacetylase Complexes J. Am. Chem. Soc. 130, 2184-2194
21. Chang, J. W., Cognetta, A. B., Niphakis, M. J., and Cravatt, B. F. (2013) Proteome-Wide Reactivity Profiling Identifies Diverse Carbamate Chemotypes Tuned for Serine Hydrolase Inhibition ACS Chem. Biol. 8, 1590-1599
22. Sieber, S. A., Niessen, S., Hoover, H. S., and Cravatt, B. F. (2006) Proteomic profiling of metalloprotease activities with cocktails of active-site probes Nat. Chem. Biol. 2, 274-281
23. Paulick, M. G. and Bogyo, M. (2011) Development of activity-based probes for cathepsin X ACS Chem. Biol. 6, 563-572
24. Pozdnyakov, N., Murrey, H. E., Crump, C. J., Pettersson, M., Ballard, T. E., Ende, C. W. am, Ahn, K., Li, Y.-M., Bales, K. R., and Johnson, D. S. (2013) Secretase Modulator (GSM) Photoaffinity Probes Reveal Distinct Allosteric Binding Sites on Presenilin J. Biol. Chem. 288, 9710-9720
25. Wright, A. T. and Cravatt, B. F. (2007) Chemical Proteomic Probes for Profiling Cytochrome P450 Activities and Drug Interactions In Vivo Chem. Biol. 14, 1043-1051
26. Duckworth, B. P., Wilson, D. J., Nelson, K. M., Boshoff, H. I., Barry, C. E., and Aldrich, C. C. (2012) Development of a selective activity-based probe for adenylating enzymes: profiling MbtA Involved in siderophore biosynthesis from Mycobacterium tuberculosis ACS Chem. Biol. 7, 1653-1658
27. Verhoest, P. R., Chapin, D. S., Corman, M., Fonseca, K., Harms, J. F., Hou, X., Marr, E. S., Menniti, F. S., Nelson, F., OConnor, R., Pandit, J., Proulx-LaFrance, C., Schmidt, A. W., Schmidt, C. J., Suiciak, J. A., and Liras, S. (2009) Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia J. Med. Chem. 52, 5188-5196
28. Charych, E. I., Jiang, L.-X., Lo, F., Sullivan, K., and Brandon, N. J. (2010) Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: Implications for the treatment of schizophrenia J. Neurosci. 30, 9027-9037
29. Kotera, J., Sasaki, T., Kobayashi, T., Fujishige, K., Yamashita, Y., and Omori, K. (2004) Subcellular Localization of Cyclic Nucleotide Phosphodiesterase Type 10A Variants, and Alteration of the Localization by cAMP-dependent Protein Kinase-dependent Phosphorylation J. Biol. Chem. 279, 4366-4375
30. Lenz, T., Fischer, J. J., and Dreger, M. (2011) Probing small molecule-protein interactions: A new perspective for functional proteomics J. Proteomics 75, 100-115
31. Di, L., Whitney-Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., Reyner, E. L., Lee, C., Feng, B., Rotter, C., Varma, M. V., Kempshall, S., Fenner, K., El-kattan, A. F., Liston, T. E., and Troutman, M. D. (2011) Development of a new permeability assay using low-efflux MDCKII cells J. Pharm. Sci. 100, 4974-4985
32. Lomenick, B., Olsen, R. W., and Huang, J. (2011) Identification of Direct Protein Targets of Small Molecules ACS Chem. Biol. 6, 34-46
33. Cox, J. and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification Nat. Biotechnol. 26, 1367-1372
34. Mellacheruvu, D., Wright, Z., Couzens, A. L., Lambert, J.-P., St-Denis, N. A., Li, T., Miteva, Y. V., Hauri, S., Sardiu, M. E., Low, T. Y., Halim, V. A., Bagshaw, R. D., Hubner, N. C., al-Hakim, A., Bouchard, A., Faubert, D., Fermin, D., Dunham, W. H., Goudreault, M., Lin, Z.-Y., Badillo, B. G., Pawson, T., Durocher, D., Coulombe, B., Aebersold, R., Superti-Furga, G., Colinge, J., Heck, A. J. R., Choi, H., Gstaiger, M., Mohammed, S., Cristea, I. M., Bennett, K. L., Washburn, M. P., Raught, B., Ewing, R. M., Gingras, A.-C., and Nesvizhskii, A. I. (2013) The CRAPome: A contaminant repository for affinity purification-mass spectrometry data Nat. Methods 10, 730-736
35. McFedries, A., Schwaid, A., and Saghatelian, A. (2013) Methods for the Elucidation of Protein-Small Molecule Interactions Chem. Biol. 20, 667-673
36. Dadvar, P., OFlaherty, M., Scholten, A., Rumpel, K., and Heck, A. J. R. (2009) A chemical proteomics based enrichment technique targeting the interactome of the PDE5 inhibitor PF-4540124 Mol. BioSyst. 5, 472-482
37. Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., Boesche, M., Delling, M., Dümpelfeld, B., Eberhard, D., Huthmacher, C., Mathieson, T., Poeckel, D., Reader, V., Strunk, K., Sweetman, G., Kruse, U., Neubauer, G., Ramsden, N. G., and Drewes, G. (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes Nat. Biotechnol. 29, 255-265
38. Speers, A. E. and Cravatt, B. F. (2009) Activity-Based Protein Profiling (ABPP) and Click Chemistry (CC)-ABPP by MudPIT Mass Spectrometry Curr. Protoc. Chem. Biol. 1, 29-41